NCT04094883View on ClinicalTrials.gov

Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

October 9, 2019

Primary Completion Date

September 1, 2020

Study Completion Date

September 1, 2020

Conditions
Neisseria Gonorrhoeae Infection
Interventions
BIOLOGICAL

Meningococcal Group B Vaccine

All participants will receive the 4CMenB vaccine, 0.5 mL, at entry (Day 0) and at week 5.

Trial Locations (1)

27514

University of North Carolina Health Care, Chapel Hill

All Listed Sponsors
collaborator

North Carolina Translational and Clinical Sciences Institute

OTHER

lead

University of North Carolina, Chapel Hill

OTHER

NCT04094883 - Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine | Biotech Hunter | Biotech Hunter